{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:18:44Z","timestamp":1787894324052,"version":"build-2784847793"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Prader-Willi syndrome (PWS) is a complex disorder resulting from the failure of expression of paternal alleles in the PWS region of chromosome 15. The PWS phenotype resembles that observed in the classic non-PWS GH deficiency (GHD), including short stature, excessive fat mass, and reduced muscle mass. To date, a small number of studies on the long-term effects of GH treatment are available in adult subjects with PWS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this longitudinal study, 12 obese subjects with PWS (GHD\/non-GHD 6\/6) were treated for a median of 17 years, with a median GH dose of 0.35 mg\/day. The median age was 27.1 years. Anthropometric, body composition, hormonal, biochemical, and blood pressure variables were analyzed in all subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Waist circumference was significantly lower at the end of the treatment period (p-value=0.0449), while body mass index (BMI) did not differ significantly. Compared to the baseline, a highly significant reduction of Fat Mass % (FM%) was observed (p-value=0.0005). IGF-I SDS values significantly increased during GH therapy (p-value=0.0005). A slight impairment of glucose homeostasis was observed after GH therapy, with an increase in the median fasting glucose levels, while insulin, HOMA-IR, and HbA1c values remained unchanged. Considering GH secretory status, both subjects with and without GHD showed a significant increase in IGF-I SDS and a reduction of FM% after GH therapy (p-value= 0.0313 for all).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our results indicate that long-term GH treatment has beneficial effects on body composition and body fat distribution in adults with PWS associated with obesity. However, the increase in glucose values during GH therapy should be considered, and continuous surveillance of glucose metabolism is mandatory during long-term GH therapy, especially in subjects with obesity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1198616","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:43:16Z","timestamp":1685076196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term effects of GH therapy in adult patients with Prader-Willi syndrome: a longitudinal study"],"prefix":"10.3389","volume":"14","author":[{"given":"Graziano","family":"Grugni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sartorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Soranna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Grugni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Crin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2018-105301","article-title":"Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study","volume":"56","author":"Butler","year":"2019","journal-title":"J Med Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-015-0312-9","article-title":"Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings","volume":"38","author":"Angulo","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00002-4","article-title":"Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction","volume":"9","author":"Tauber","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2016.11.003","article-title":"Diagnosis and treatment of GH deficiency in Prader-Willi syndrome","volume":"30","author":"Grugni","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0829","article-title":"The impact of growth hormone\/insulin-like growth factor-I axis and nocturnal breathing disorders on cardiovascular features of adult patients with Prader-Willi syndrome","volume":"90","author":"Marzullo","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-019-09502-2","article-title":"RESTARE. Prader-Willi syndrome: an uptodate on endocrine and metabolic complications","volume":"20","author":"Muscogiuri","year":"2019","journal-title":"Rev Endocr Metab Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3888","article-title":"2011 Growth hormone in Prader-Willi syndrome clinical care guidelines workshop participants. Growth hormone research society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome","volume":"98","author":"Deal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2019-000630","article-title":"Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis","volume":"4","author":"Passone","year":"2020","journal-title":"BMJ Paediatr Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S70068","article-title":"Growth hormone therapy for Prader-Willi syndrome: challenges and solutions","volume":"12","author":"Grugni","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14372","article-title":"The use of growth hormone therapy in adults with Prader-Willi syndrome: a systematic review","volume":"94","author":"Frixou","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab406","article-title":"Growth hormone treatment for adults with Prader-Willi syndrome: a meta-analysis","volume":"106","author":"Rosenberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122667","article-title":"Twenty years of GH treatment in adults with Prader-Willi syndrome","volume":"10","author":"Sj\u00f6str\u00f6m","year":"2021","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1257","article-title":"Reference values for IGF-I serum concentrations: comparison of six immunoassays","volume":"101","author":"Chanson","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01967","article-title":"The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index","volume":"153","author":"Corneli","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113596","article-title":"Changes of body weight and body composition in obese patients with Prader-Willi syndrome at 3 and 6 years of follow-up: a retrospective cohort study","volume":"9","author":"Bedogni","year":"2020","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B17","unstructured":""},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.9.7814","article-title":"Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution","volume":"86","author":"Goldstone","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2006.193","article-title":"Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity","volume":"14","author":"Theodoro","year":"2006","journal-title":"Obesity"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-015-0266-y","article-title":"Does segmental body composition differ in women with Prader-Willi syndrome compared to women with essential obesity","volume":"38","author":"Bedogni","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3127","article-title":"Metabolic and adipose tissue signatures in adults with Prader-Willi syndrome: a model of extreme adiposity","volume":"100","author":"Lacroix","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2265.2011.04303.x","article-title":"Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis","volume":"77","author":"Sanchez-Ortiga","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/apa.12898","article-title":"Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition","volume":"104","author":"H\u00f6ybye","year":"2015","journal-title":"Acta Paediatr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104379","article-title":"The consequences of hyperphagia in people with Prader-Willi syndrome: a systematic review of studies of morbidity and mortality","volume":"65","author":"Bellis","year":"2022","journal-title":"Eur J Med Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13023-019-1214-2","article-title":"Causes of death in Prader-Willi syndrome: lessons from 11 years' experience of a national reference center","volume":"14","author":"Pacoricona Alfaro","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ajmg.a.60688","article-title":"Contributing factors of mortality in Prader-Willi syndrome","volume":"179","author":"Proffitt","year":"2019","journal-title":"Am J Med Genet A"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14047","article-title":"Clinical & scientific advisory board of the international Prader-Willi syndrome organisation. Letter regarding \"Prevalence of growth hormone deficiency in previously GH-treated young adults with Prader-Willi syndrome\" by Donze et\u00a0al","volume":"91","author":"H\u00f6ybye","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13023-020-01651-x","article-title":"Clinical and scientific advisory board of the international Prader-Willi syndrome organisation. Time for a general approval of growth hormone treatment in adults with Prader-Willi syndrome","volume":"16","author":"H\u00f6ybye","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2016.05.010","article-title":"Genetic obesity study group of the Italian society of pediatric endocrinology and diabetology (ISPED). Disorders of glucose metabolism in Prader-Willi syndrome: results of a multicenter Italian cohort study","volume":"26","author":"Fintini","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/ije\/dyi253","article-title":"What aspects of body fat are particularly hazardous and how do we measure them","volume":"35","author":"Snijder","year":"2006","journal-title":"Int J Epidemiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1198616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:43:19Z","timestamp":1685076199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1198616\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":32,"alternative-id":["10.3389\/fendo.2023.1198616"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1198616","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"article-number":"1198616"}}